JP7004665B2 - 癌治療用の前酵素の組成物 - Google Patents

癌治療用の前酵素の組成物 Download PDF

Info

Publication number
JP7004665B2
JP7004665B2 JP2018553345A JP2018553345A JP7004665B2 JP 7004665 B2 JP7004665 B2 JP 7004665B2 JP 2018553345 A JP2018553345 A JP 2018553345A JP 2018553345 A JP2018553345 A JP 2018553345A JP 7004665 B2 JP7004665 B2 JP 7004665B2
Authority
JP
Japan
Prior art keywords
trypsinogen
chymotrypsinogen
cancer
weight ratio
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018553345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511525A (ja
JP2019511525A5 (cg-RX-API-DMAC7.html
Inventor
ジュリアン・ケンヨン
ラルフ・ブラント
Original Assignee
プロパンク・ピーティーワイ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロパンク・ピーティーワイ・リミテッド filed Critical プロパンク・ピーティーワイ・リミテッド
Publication of JP2019511525A publication Critical patent/JP2019511525A/ja
Publication of JP2019511525A5 publication Critical patent/JP2019511525A5/ja
Application granted granted Critical
Publication of JP7004665B2 publication Critical patent/JP7004665B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21001—Chymotrypsin (3.4.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2018553345A 2016-04-12 2017-04-12 癌治療用の前酵素の組成物 Active JP7004665B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662321370P 2016-04-12 2016-04-12
US62/321,370 2016-04-12
PCT/AU2017/050323 WO2017177270A1 (en) 2016-04-12 2017-04-12 Composition of proenzymes for cancer treatment

Publications (3)

Publication Number Publication Date
JP2019511525A JP2019511525A (ja) 2019-04-25
JP2019511525A5 JP2019511525A5 (cg-RX-API-DMAC7.html) 2020-05-07
JP7004665B2 true JP7004665B2 (ja) 2022-02-04

Family

ID=60041280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018553345A Active JP7004665B2 (ja) 2016-04-12 2017-04-12 癌治療用の前酵素の組成物

Country Status (6)

Country Link
US (1) US20190134166A1 (cg-RX-API-DMAC7.html)
EP (1) EP3442564B1 (cg-RX-API-DMAC7.html)
JP (1) JP7004665B2 (cg-RX-API-DMAC7.html)
CN (1) CN109152823A (cg-RX-API-DMAC7.html)
AU (1) AU2017250010A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017177270A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2941348T3 (es) * 2015-11-12 2023-05-22 Propanc Pty Ltd Composición de proenzima
US12419938B2 (en) 2015-11-12 2025-09-23 Propanc Pty Ltd Proenzyme composition
ES2965358T3 (es) 2016-01-29 2024-04-15 Propanc Pty Ltd Tratamiento del cáncer
US11141466B2 (en) * 2017-06-22 2021-10-12 CSL Behring Lengnau AG Modulation of FVIII immunogenicity by truncated VWF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508307A (ja) 2009-10-22 2013-03-07 プロパンク・ピーティーワイ・リミテッド トリプシノーゲンおよび／またはキモトリプシノーゲン、ならびに、セレン化合物、バニロイド化合物および細胞質解糖系還元剤より選択された活性剤を含む癌治療のための医薬組成物。

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514388A (en) * 1983-03-22 1985-04-30 Psaledakis Nicholas G Proteolytic enzymes in the zymogen form to treat sarcoma cells
CZ283972B6 (cs) * 1995-05-17 1998-07-15 František Mudr. Trnka Farmaceutický prostředek s modulačním účinkem na zhoubné nádory a jeho použití
CZ307195B6 (cs) * 2013-11-18 2018-03-14 František Trnka Farmaceutická kompozice obsahující směs proenzymů a enzymů
ES2965358T3 (es) 2016-01-29 2024-04-15 Propanc Pty Ltd Tratamiento del cáncer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508307A (ja) 2009-10-22 2013-03-07 プロパンク・ピーティーワイ・リミテッド トリプシノーゲンおよび／またはキモトリプシノーゲン、ならびに、セレン化合物、バニロイド化合物および細胞質解糖系還元剤より選択された活性剤を含む癌治療のための医薬組成物。

Also Published As

Publication number Publication date
WO2017177270A1 (en) 2017-10-19
CN109152823A (zh) 2019-01-04
EP3442564A4 (en) 2019-12-04
EP3442564A1 (en) 2019-02-20
US20190134166A1 (en) 2019-05-09
JP2019511525A (ja) 2019-04-25
EP3442564B1 (en) 2023-12-06
AU2017250010A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
RU2161487C2 (ru) Применение производных 2-гидрокси-5-фенилазобензойной кислоты в качестве химиопрофилактических и химиотерапевтических агентов при раке ободочной кишки
EP2542058B1 (en) Effective sensitizing dose of a gelled immunomodulating topical composition
JP7004665B2 (ja) 癌治療用の前酵素の組成物
JP5871805B2 (ja) トリプシノーゲンおよびキモトリプシノーゲンを含む癌治療のための医薬組成物。
EP2514483A1 (en) Adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of clinical manifestations associated with these diseases, such as cachexia, and remedying adverse effects of drugs and treatments, such as immunodepression, neutropenia and lymphocytopenia, comprising the association or combination of a specially selected biological response modifier and other antineoplastic compounds and/or other treatments
BR112021006407A2 (pt) uso de inibidores do egfr para ceratodermas
JPWO2019074116A1 (ja) Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
CN108430472A (zh) 用于治疗卵巢癌的hdac抑制剂与抗-pd-l1抗体的组合
KR20210068455A (ko) 종양 치료에서 오존화 오일을 포함하는 제제
Gu et al. Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice
WO2022262854A1 (zh) Cly系列化合物及其制备方法和制备药物的用途
AU2016353539B2 (en) Proenzyme composition
EP2870135A1 (en) Pharmaceutical composition comprising amino-phenyl- acetic acid octadec-(z)-9-enyl ester and use thereof for treating tumors
US12419938B2 (en) Proenzyme composition
HK40002720A (en) Composition of proenzymes for cancer treatment
CA3003835C (en) Proenzyme composition
TWI757511B (zh) 乙內醯脲衍生物之用途
JP2022551672A (ja) 乳癌治療法
WO2019196621A1 (zh) 喹唑啉类化合物在治疗具有EGFRv3活化突变的癌症药物中的用途
KR20170082627A (ko) 암의 치료를 위한 신규한 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220104

R150 Certificate of patent or registration of utility model

Ref document number: 7004665

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250